Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

2.015 -0.125 (-5.84%)
Streaming Delayed Price Updated: 1:14 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Recap: Coherus BioSciences Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview For Coherus BioSciences ↗
 
Via Benzinga
News headline image
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024 ↗
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Why Coherus Biosciences Stock Tumbled on Thursday ↗
The company fell well short of expectations for its fourth quarter. 
Via The Motley Fool
News headline image
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2024 ↗
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
News headline image
Coherus Completes Divestiture of Ophthalmology Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Why Coherus BioSciences Stock Jumped Today ↗
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses. 
Via The Motley Fool
News headline image
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Why Coherus BioSciences Stock Is Sinking Today ↗
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long. 
Via The Motley Fool
News headline image
Why Coherus Biosciences Popped Today ↗
Coherus is divesting its non-core ophthalmology franchise. 
Via The Motley Fool
News headline image
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the... 
Via Benzinga
News headline image
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? ↗
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. 
Via Benzinga
News headline image
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? ↗
Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price. 
Via InvestorPlace
News headline image
Why Is B. Riley Financial (RILY) Stock Down 11% Today? ↗
B. Riley Financial stock is falling on Monday as RILY investors react to reports of an SEC probe and the company's stance on the news. 
Via InvestorPlace
Topics Regulatory Compliance
News headline image
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? ↗
Coherus BioSciences stock is rising on Monday as CHRS investors react to a $170 million divestment of its CIMERLI ophthalmology franchise. 
Via InvestorPlace
News headline image
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket ↗
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.